The use of ciclosporin in psoriasis

Journal of Dermatological Treatment

Volumn 16, Issue 5-6, 2005, Pages 258-277

  Berth Jones, John ^a  

^a UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

Author keywords

Ciclosporin; Psoriasis

Indexed keywords

AMLODIPINE; BASILIXIMAB; CALCIPOTRIOL; CALCIUM ANTAGONIST; CLOBETASOL PROPIONATE; CYCLOSPORIN A; DICLOFENAC; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DITHRANOL; ENALAPRIL; ETRETIN; FELODIPINE; FISH OIL; FUMARIC ACID; GEMFIBROZIL; HYDROXYUREA; HYPERICUM PERFORATUM EXTRACT; INFLIXIMAB; ISRADIPINE; KETOCONAZOLE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; RAPAMYCIN; RETINOID; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VERAPAMIL;

ABDOMINAL PAIN; ACNE; ARTHROPATHY; ASTHENIA; B CELL LYMPHOMA; BACKACHE; BASAL CELL CARCINOMA; BLADDER CARCINOMA; CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG MECHANISM; DYSPEPSIA; ERYTHROMELALGIA; FACE EDEMA; FATIGUE; FLUSHING; FOLLICULITIS; FOLLOW UP; FUNGAL MENINGITIS; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; GLUCOSE TOLERANCE; GYNECOMASTIA; HEADACHE; HEPATITIS B; HEPATITIS C; HERPES SIMPLEX; HUMAN; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRICHOSIS; HYPERURICEMIA; HYPOMAGNESEMIA; INFECTION; KERATOSIS; LONG TERM CARE; LYMPHOPROLIFERATIVE DISEASE; MUSCLE CRAMP; MYCOSIS FUNGOIDES; NAUSEA; NEOPLASM; NEPHROTOXICITY; NEUROLOGIC DISEASE; PARESTHESIA; PERIPHERAL EDEMA; PRIORITY JOURNAL; PSORIASIS; PUVA; RASH; REBOUND; RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATIC DISEASE; SKIN DISEASE; T LYMPHOCYTE; TREATMENT WITHDRAWAL; TREMOR; UREMIA; VOMITING;

ADULT; CHILD; CYCLOSPORINE; DERMATOLOGIC AGENTS; FEMALE; HUMANS; PREGNANCY; PSORIASIS;

EID: 31644442734     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630500423914     Document Type: Review

References (223)

1. Borel JF, Feurer C, Gubler HU. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions. 1976;6:468-75.
2. Nicolas JF, Chamchick N, Thivolet J, Wijdenes G, Morel P, Revillard JP. CD4 antibody treatment of severe psoriasis. Lancet. 1991;338:321.
3. Gottlieb SL, Gilleaudeau P, Johnson R, Estes L, Woodworth TG, Gottlieb AB, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995;1:442-7.
4. Mease PJ, Goffe BS, Metz J, Vanderstoep A, Finck B, Burge DT. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000;356:385-90.
5. Oh CJ, Das KM, Gottlieb AB. Treatment with anti-tumor necrosis factor α (TNFα) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol. 2000;42:829-30.
6. Liu J, Farmer JD, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophylin-cyclosporin A and FKBP-FK506 complexes. Cell. 1991;66:807-15.
7. Thompson CB, Lindsten T, Ledbetter JA, Kunkel SL, Young HA, Emerson SG, et al. CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc Natl Acad Sci U S A. 1989;86:1333-7.
8. Elder JT, Hammerberg C, Cooper KD, Kojima T, Nair RP, Ellis CN, et al. Cyclosporin A rapidly inhibits epidermal cytokine expression in psoriasis lesions, but not in cytokine-stimulated cultured keratinocytes. J Invest Dermatol. 1993;101:761-6.
9. Cooper KD, Baadsgaard O, Ellis CN, Duell E, Voorhees JJ. Mechanisms of cyclosporine A inhibition of antigen presenting activity in uninvolved and lesional psoriatic epidermis. J Invest Dermatol. 1990;94:649-56.
10. Demidem A, Taylor JR, Grammer SF, Streilein JW. T-lymphocyte-activating properties of epidermal antigen-presenting cells from normal and psoriatic skin: evidence that psoriatic epidermal antigen-presenting cells resemble cultured normal Langerhans cells. J Invest Dermatol. 1991;97:454-60.
11. Stellato C, de Paulis A, Ciccarelli A. Anti-inflammatory effect of cyclosporin A on human skin mast cells. J Invest Dermatol. 1992;98:800-4.
12. Triggiani M, Cirillo R, Lichtenstein LM, Marone G. Inhibition of histamine and prostaglandin D2 release from human lung mast cells by cyclosporin A. Int Arch Allergy Appl Immunol. 1989;88:253-5.
13. Al-Daraji WI, Grant KR, Ryan K, Saxton A, Reynolds NJ. Localization of calcineurin/NFAT in human skin and psoriasis and inhibition of calcineurin/NFAT activation in human keratinocytes by cyclosporin A. J Invest Dermatol. 2002;118:779-88.
14. Kanitakis J, Thivolet J. Cyclosporin. An immunosuppressant affecting epithelial cell proliferation. Arch Dermatol. 1990;126:369-75.
15. Karashima T, Hachisuka H, Sasai Y. FK506 and cyclosporin A inhibit growth factor-stimulated human keratinocyte proliferation by blocking cells in the G0/G1 phases of the cell cycle. J Dermatol Sci. 1996;12:246-54.
16. Fisher GJ, Duell EA, Nickoloff BJ, Annesley TM, Kowalke JK, Ellis CN, et al. Levels of cyclosporine in epidermis of treated psoriasis patients differentially inhibit growth of keratinocytes cultured in serum-free versus serum-containing media. J Invest Dermatol. 1988;91:142-6.
17. Urabe A, Kanitakis J, Viac J, Thivolet J. Cyclosporin A inhibits directly in vivo keratinocyte proliferation of living human skin. J Invest Dermatol. 1989;92:755-7.
18. Won YH, Sauder DN, McKenzie RC. Cyclosporin A inhibits keratinocyte cytokine gene expression. Br J Dermatol. 1994;130:312-19.
19. Niederberger W, Lemaire M, Maurer G, et al. Distribution and binding of cyclosporine in blood and tissue. Transplant Proc. 1983;15:2419-21.
20. Lemaire M, Tillement JP. Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood. J Pharm Pharmacol. 1982;34:715-18.
21. Ptachcinski RJ, Venkataramanan R, Burckart GJ. Clinical pharmacokinetics of cyclosporin. Clin Pharmacokinet. 1986;11:107-32.
22. Erkko P, Granlund H, Nuutinen M, Reitamo S. Comparison of cyclosporin A pharmacokinetics of a new microemulsion formulation and standard oral preparation in patients with psoriasis. Br J Dermatol. 1997;136:82-8.
23. Wood AJ, Maurer G, Niederberger W, Beveridge T. Cyclosporine: pharmacokinetics, metabolism and drug interactions. Transplant Proc. 1983;15:2409-12.
24. Elder CA, Moore M, Chang CT, Jin J, Charnick S, Nedelman J, et al. Efficacy and pharmacokinetics of two formulations of cyclosporine A in patients with psoriasis. J Clin Pharmacol. 1995;35:865-75.
25. Mueller EA, Kovarik JM, van Bree JB, Grevel J, Lucker PW, Kutz K. Influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporin in a crossover comparison with the market formulation. Pharm Res. 1994;11:151-5.
26. Chawla M, Ali M, Marks R. Comparison of the steady state pharmacokinetics of two formulations of cyclosporin in patients with atopic dermatitis. Br J Dermatol. 1996;135(Suppl 48):S9-S14.
27. Koo J. A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. Br J Dermatol. 1998;139:88-95.
28. Mueller W, Herrman H. Cyclosporin A for psoriasis. N Engl J Med. 1979;301:555.
29. Ellis CN, Gorsulowsky DC, Hamilton TA, Billings JK, Brown MD, Headington JT, et al. Cyclosporin improves psoriasis in a double-blind study. JAMA. 1986;256:3110-16.
30. Van Hooff JP, Leunissen KML, Van der Staak W. Cyclosporin and psoriasis. Lancet. 1985;1:335.
31. Picascia DD, Garden JM, Freinkel RK, Roenigk HH Jr. Treatment of resistant severe psoriasis with systemic cyclosporin. J Am Acad Dermatol. 1987;17:408-14.
32. Van Joost T, Bos JD, Heule F, Meinardi MM. Low-dose cyclosporin A in severe psoriasis. A double-blind study. Br J Dermatol. 1988;118:183-90.
33. Ellis CN, Fradin MS, Messana JM, Brown MD, Siegel MT, Hartley AH, et al. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N Engl J Med. 1991;324:277-84.
34. Amerio P, Gravante M, Andreassi M, Masci S. Cyclical immunotherapy in patients with psoriasis. Acta Derm Venereol. 1994;Suppl 186:101-2.
35. Griffiths CEM, Powles AV, McFadden J, Baker BS, Valdimarsson H, Fry L. Long-term cyclosporin for psoriasis. Br J Dermatol. 1989;120:253-60.
36. Levell NJ, Shuster S, Munro CS, Friedmann PS. Remission of ordinary psoriasis following a short clearance course of cyclosporin. Acta Derm Venereol. 1995;75:65-9.
37. Harper JI, Keat AC, Staughton RC. Cyclosporin for psoriasis. Lancet. 1984;2:981-2.
38. Van Hooff JP, Leunissen KML, v d Staak W. Cyclosporin and psoriasis. Lancet. 1985;1:335.
39. Fry L, Griffiths CEM, Powles AV, Baker BS, Valdimarsson H. Long-term cyclosporine in the management of psoriasis. Transplant Proc. 1988;20(Suppl 4):23-5.
40. Higgins E, Munro C, Marks J, Friedmann PS, Shuster S. Relapse rates in moderately severe chronic psoriasis treated with cyclosporin A. Br J Dermatol. 1989;121:71-4.
41. Dubertret L, Perussel M, Robiola O, Feutren G. Cyclosporin in psoriasis. A long-term randomised study on 37 patients. Acta Derm Venereol. 1989;Suppl 146:36.
42. Heule F, Bousema MT, Laeijendecker R, van Joost T. Three long-term regimens with cyclosporin for psoriasis vulgaris. Acta Derm Venereol Suppl. 1989;146:171-5.
43. Cimitan A, Fantini F, Giannetti A. Clinical trial with cyclosporin A. Acta Derm Venereol. 1989;Suppl 146:159-62.
44. Timonen P, Friend D, Abeywickrama K, Laburte C, von Graffenried B, Feutrien G. Efficacy of low-dose cyclosporin A in psoriasis: results of dose-finding studies. Br J Dermatol. 1990;122(Suppl 36):33-9.
45. Korstanje MJ, Van de Staak WJ. Long-term treatment of psoriasis with cyclosporin A - side-effects, minimal effective dose and cyclosporin blood levels. Clin Exp Dermatol. 1991;16:8-10.
46. Christophers E, Mrowietz U, Henneicke HH, Farber L, Welzel D. Cyclosporine in psoriasis: a multicenter dose-finding study in severe plaque psoriasis. The German Multicenter Study. J Am Acad Dermatol. 1992;26:86-90.
47. Anonymous. Short- and long-term considerations concerning the management of plaque psoriasis with low-dose cyclosporin. Studio Italiano Multicentrico nella Psoriasi (SIMPSO). Dermatology. 1993;187(Suppl 1):19-29.
48. Anonymous. Cyclosporin versus etretinate: Italian multicenter comparative trial in severe plaque-form psoriasis. Italian Multicenter Study Group on Cyclosporin in Psoriasis. Dermatology. 1993;187(Suppl 1):8-18.
49. Laburte C, Grossman R, Abi-Rached J, Abeywickrama KH, Dubertret L. Efficacy and safety of oral cyclosporin A (CyA; Sandimmun) for long-term treatment of chronic severe plaque psoriasis. Br J Dermatol. 1994;130:366-75.
50. Finzi AF, Mozzanica N, Cattaneo A, Chiappino G, Pigatto PD. Effectiveness of cyclosporine treatment in severe psoriasis: a clinical and immunologic study. J Am Acad Dermatol. 1989;21:91-7.
51. Grossman RM, Chevret S, Abi-Rached J, Blanchet D, Dubertret L. Long-term safety of cyclosporine in the treatment of psoriasis. Arch Dermatol. 1996;132:623-9.
52. Berth-Jones J, Henderson CA, Munro CS, Rogers S, Chalmers RJ, Boffa MJ, et al. Treatment of psoriasis with intermittent short course cyclosporin (Neoral®). A multicentre study. Br J Dermatol. 1997;136:527-30.
53. Lowe NJ, Wieder JM, Rosenbach A, Johnson K, Kunkel R, Bainbridge C, et al. Long-term low-dose cyclosporine therapy for severe psoriasis: effects on renal function and structure. J Am Acad Dermatol. 1996;35:710-19.
54. Touw CR, Hakkaart-van Roijen L, Verboom P, Paul C, Rutten FF, Finlay AY. Quality of life outcome in psoriasis patients using intermittent cyclosporin. Br J Dermatol. 2001;144:967-72.
55. Salek MS, Finlay AY, Lewis JJ, Sumner MI. Quality of life improvement in treatment of psoriasis with intermittent short course cyclosporin (Neoral). Qual Life Res. 2004;13:91-5.
56. Powles AV, Baker BS, Valdimarsson H, Hulme B, Fry L. Four years of experience with cyclosporin A for psoriasis. Br J Dermatol. 1990;122(Suppl 36):13-19.
57. Levell NJ, Shuster S, Munro CS, Friedmann PS. Remission of ordinary psoriasis following a short clearance course of cyclosporin. Acta Derm Venereol. 1995;75:65-9.
58. Mahrle G, Schulze HJ, Farber L, Weidinger G, Steigleder GK. Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement. J Am Acad Dermatol. 1995;32:78-88.
59. Heydendael VM, Spuls PI, Opmeer BC, de Borgie CA, Reitsma JB, Goldschmidt WF, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med. 2003;349:658-65.
60. Sandhu K, Kaur I, Kumar B, Saraswat A. Efficacy and safety of cyclosporine versus methotrexate in severe psoriasis: a study from north India. J Dermatol. 2003;30:458-63.
61. Davison SC, Morris-Jones R, Powles AV, Fry L. Change of treatment from cyclosporin to mycophenolate mofetil in severe psoriasis. Br J Dermatol. 2000;143:405-7.
62. Higgins E, Munro C, Marks J, Friedmann PS, Shuster S. Relapse rates in moderately severe chronic psoriasis treated with cyclosporin A. Br J Dermatol. 1989;121:71-4.
63. Sutthipisal N, Sriwatsantsak J, Sirimachan S, Nitidandhabaprabhas P. The use of cyclosporin A in a case of recalcitrant erythrodermic psoriasis. J Int Med Res. 1988;16:485-8.
64. Reitamo S, Mustakallio KK. Cyclosporin in erythrodermic psoriasis. Acta Derm Venereol. 1989;Suppl 146:140-1.
65. Anonymous. Management of erythrodermic psoriasis with low-dose cyclosporin. Studio Italiano Multicentrico nella Psoriasi (SIMPSO). Dermatology. 1993;187(Suppl 1):30-7.
66. Meinardi MMH, Westerhof W, Bos JD. Generalized pustular psoriasis (von Zumbusch) responding to cyclosporin A. Br J Dermatol. 1987;116:269-70.
67. Matsumura N, Takematsu H, Saijo S, Hashimoto K, Togami H. Exanthematic type of pustular psoriasis consisting of two types of pustular lesion. Acta Derm Venereol. 1991;71:442-4.
68. Alli N, Gungor E, Karakayali G, Lenk N, Artuz F. The use of cyclosporin in a child with generalized pustular psoriasis. Br J Dermatol. 1998;139:754-5.
69. Korstanje MJ, Bessems PJMJ, Hulsmans RFHJ, van de Staak WJBM. Pustular psoriasis and acrodermatitis continua (Hallopeau) need high doses of systemic cyclosporin A. Dermatologica. 1989;179:90-4.
70. Fradin MS, Ellis CN, Voorhees JJ. Rapid response of Von Zumbusch psoriasis to cyclosporine. J Am Acad Dermatol. 1990;23:925-6.
71. Coulson IH, Evans CD, Holden CA. Generalised pustular psoriasis after renal transplantation - failure to suppress with cyclosporin A. Clin Exp Dermatol. 1988;13:416-17.
72. Reitamo S, Puska P, Lassus A. Cyclosporin in the treatment of palmo-plantar pustulosis. Br J Dermatol. 1989;120:857.
73. Meinardi MMHM, de Rie MA, Bos JD. Oral cyclosporin A is effective in clearing persistent pustulosis palmaris et plantaris. Acta Derm Venereol. 1990;70:77-9.
74. Gupta AK, Ellis CN, Nickoloff BJ, Goldfarb MT, Ho VC, Rocher LL, et al. Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses. A clinical and immunopathologic analysis. Arch Dermatol. 1990;126:339-50.
75. Zachariae H, Thestrup-Pedersen K. Cyclosporin A in acrodermatitis continua. Dermatologica. 1987;175:29-32.
76. Peter RU, Ruzicka T, Donhauser G, Braun-Falco O. Acrodermatitis continua-type of pustular psoriasis responds to low dose cyclosporine. J Am Acad Dermatol. 1990;23:515-16.
77. Arnold WP, Gerritsen M-JP, van de Kerkhof PCM. Response of nail psoriasis to cyclosporin. Br J Dermatol. 1993;129:750-1.
78. Cannavo SP, Guarneri F, Vaccaro M, Borgia F, Guarneri B. Treatment of psoriatic nails with topical cyclosporin: a prospective, randomized placebo-controlled study. Dermatology. 2003;206:153-6.
79. Harper JI, Zemelman V, Keat ACS, Staughton RCD. Cyclosporine for psoriasis: beneficial effect in refractory skin and joint disease. Transplant Proc. 1988;20(Suppl 4):63-7.
80. Steinsson K, Jonsdottir I, Valdimarsson H. Cyclosporin A in psoriatic arthritis: an open study. Ann Rheum Dis. 1990;49:603-6.
81. Gupta AK, Matteson EL, Ellis CN, Ho VC, Tellner DC, Voorhees JJ, et al. Cyclosporine in the treatment of psoriatic arthritis. Arch Dermatol. 1989;125:507-10.
82. Salvarani C, Macchioni P, Boiardi L, Rossi F, Casadei Maldini M, Mancini R, et al. Low dose cyclosporine A in psoriatic arthritis: relation between soluble interleukin 2 receptors and response to therapy. J Rheumatol. 1992;19:74-9.
83. Sarzi-Puttini P, Cazzola M, Panni B, Turiel M, Fiorini T, Belai-Beyene N, et al. Long-term safety and efficacy of low-dose cyclosporin A in severe psoriatic arthritis. Rheumatol Int. 2002;21:234-8.
84. Vaccaro M, Borgia F, Guarneri F, Blandino A, Cannavo SP, Guarnieri B. Successful treatment of pustulotic arthroosteitis (Sonozaki syndrome) with systemic cyclosporin. Clin Exp Dermatol. 2001;26:45-7.
85. Bougneres PF, Carel JC, Castano CL, Boitard C, Gardin JP, Landais P, et al. Factors associated with early remission of type I diabetes in children treated with cyclosporine. N Engl J Med. 1988;318:663-70.
86. Hulton SA, Jadresic L, Risdon RA, Dillon MJ, Barratt TM. Effect of cyclosporin A (CYA) on renal function in childhood nephrotic syndrome. Pediatr Nephrol. 1991;5:C25.
87. Collaborative study group of Sandimmun® in nephrotic syndrome, Safety and efficacy of cyclosporin A (Sandimmun®) in idiopathic nephrotic syndrome. Clin Nephrol. 1991;35:S48-S60.
88. Heckmatt J, Hasson N, Saunders C, Thompson N, Peters AM, Cambridge G, et al. Cyclosporin in juvenile dermatomyositis. Lancet. 1989;1:1063-6.
89. Berth-Jones J, Finlay AY, Zaki I, Tan B, Goodyear H, Lewis-Jones S, et al. Cyclosporine in severe childhood atopic dermatitis: a multicentre study. J Am Acad Dermatol. 1996;34:1016-21.
90. Zaki I, Emerson R, Allen BR. Treatment of severe atopic dermatitis in childhood with cyclosporin. Br J Dermatol. 1996;135(Suppl 48):21-4.
91. Harper JI, Ahmed IA, Barclay G, Lacour M, Hoeger P, Cork MJ, et al. Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. Br J Dermatol. 2000;142:52-8.
92. Perrett CM, Ilchyshyn A, Berth-Jones J. Cyclosporin in childhood psoriasis. J Dermatol Treat. 2003;14:113-18.
93. Mahe E, Bodemer C, Pruszkowski A, Teillac-Hamel D, de Prost Y. Cyclosporine in childhood psoriasis. Arch Dermatol. 2001;137:1532-3.
94. Cooney GF, Habucky K, Hoppu K. Cyclosporin pharmacokinetics in pediatric transplant recipients. Clin Pharmacokinet. 1997;32:481-95.
95. Mason RJ, Thomson AW, Whiting PH, Gray ES, Brown PA, Catto GR, et al. Cyclosporine induced fetotoxicity in the rat. Transplantation. 1985;39:9-12.
96. Gaughan WJ, Moritz MJ, Radomski JS, Burke JF Jr, Armenti VT. National Transplantation Pregnancy Registry: report on outcomes in cyclosporine-treated female kidney transplant recipients with an interval from transplant to pregnancy of greater than five years. Am J Kidney Dis. 1996;28:266-96.
97. Wright S, Glover M, Baker H. Psoriasis, cyclosporine, and pregnancy. Arch Dermatol. 1991;127:426.
98. Raddadi AA, Damanhoury ZB. Cyclosporin and pregnancy. Br J Dermatol. 1999;140:1197-8.
99. Finch TM, Tan CY. Pustular psoriasis exacerbated by pregnancy and controlled by cyclosporin A. Br J Dermatol. 2000;142:582-4.
100. Sowden JM, Berth-Jones J, Ross JS, Motley RJ, Marks R, Finlay AY, et al. Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis. Lancet. 1991;338:137-40.
101. Young EW, Ellis CN, Messana SM, Johnson KJ, Leichtman AB, Mihatsch MJ, et al. A prospective study of renal structure and function in psoriasis patients treated with cyclosporin. Kidney Int. 1994;46:1216-22.
102. Powles AV, Hardman CM, Porter WM, Cook T, Hulme B, Fry L. Renal function after 10 years treatment with cyclosporin for psoriasis. Br J Dermatol. 1998;138:443-9.
103. Korstanje MJ, Bilo HJG, Stoof TJ. Sustained renal function loss in psoriasis patients after withdrawal of low-dose cyclosporin therapy. Br J Dermatol. 1992;127:501-4.
104. Zachariae H, Kragballe K, Hansen HE, Marcussen N, Olsen S. Renal biopsy findings in long-term cyclosporin treatment of psoriasis. Br J Dermatol. 1997;136:531-5.
105. Luke RG. Mechanism of cyclosporine-induced hypertension. Am J Hypertens. 1991;4:468-71.
106. Krupp P, Monka C. Side-effect profile of cyclosporin A in patients treated for psoriasis. Br J Dermatol. 1990;122(Suppl 36):47-56.
107. Cainelli F, Concia E, Vento S. Cryptococcal meningitis during cyclosporin treatment in a patient with psoriasis. Br J Dermatol. 2000;143:1327-8.
108. Kanamori H, Fukawa H, Maruta A, Harano H, Kodama F, Matsuzaki M, et al. Case report: fulminant hepatitis C viral infection after allogeneic bone marrow transplantation. Am J Med Sci. 1992;303:109-11.
109. Frentz G, Olsen JH. Malignant tumours and psoriasis: a follow up study. Br J Dermatol. 1999;140:237-42.
110. Margolis D, Bilker W, Hennessy S, Vittorio C, Santanna J, Strom BL. The risk of malignancy associated with psoriasis. Arch Dermatol. 2001;137:778-83.
111. Paul CF, Ho VC, McGeown C, Christophers E, Schmidtmann B, Guillaume JC, et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol. 2003;120:211-16.
112. Olsham AF, Mattison DR, Zwanenburg TSB. Cyclosporine A: a review of genotoxicity and potential for adverse human reproductive and developmental effects. Mutat Res. 1994;317:163-73.
113. Rosenkranz HS, Klopman G. A structural analysis of the genotoxic and carcinogenic potentials of cyclosporin A. Mutagenesis. 1992;7:115-18.
114. Van den Borne BEEM, Landewe RBM, Houkes I, Schild F, van der Heyden PC, Hazes JM, et al. No increased risk of malignancies and mortality in cyclosporin A-treated patients with rheumatoid arthritis. Arthritis Rheum. 1998;41:1930-7.
115. Cliff S, Pettengell R, Gharge S, Marsden RA. B-cell lymphoma developing in a patient on cyclosporin for recalcitrant psoriasis. Br J Dermatol. 1999;140:763-5.
116. Koo JY, Kadonaga JN, Wintroub BV, Lozada-Nur FI. The development of B-cell lymphoma in a patient with psoriasis treated with cyclosporine. J Am Acad Dermatol. 1992;26:836-40.
117. Puig L, Puig J, de Moragas JM. Transient monoclonal gammopathy associated with cyclosporin treatment of psoriasis. Br J Dermatol. 1995;133:149-50.
118. Paquet P, Pierard GE. Breast and lung cancers in 2 cyclosporin treated psoriatic women. Dermatology. 1998;196:450-2.
119. Yamamoto T, Katayama I, Nishioka K. Adenocarcinoma of the mouth in a patient with psoriasis under short term cyclosporin therapy. Dermatology. 1996;193:72-3.
120. Grossman RM, Maugee E, Dubertret L. Cervical intraepithelial neoplasia in a patient receiving long-term cyclosporin for the treatment of severe plaque psoriasis. Br J Dermatol. 1996;135:147-8.
121. Camp RDR. Psoriasis. In: Champion RH, Burton JL, Burns DA, Breathnach SM, editors. Textbook of dermatology, Vol 2. London: Blackwell Scientific Publications, 1998: 1589-650.
122. Van de Kerkhof PCM, De Rooij MJM. Multiple squamous cell carcinomas in a psoriatic patient following high-dose photochemotherapy and cyclosporin treatment: response to long-term acitretin maintenance. Br J Dermatol. 1997;136:275-8.
123. Oxholm A, Thomsen K, Menne T. Squamous cell carcinomas in relation to cyclosporin therapy of non malignant skin disorders. Acta Derm Venereol. 1989;69:89-90.
124. Bos JD, Meinardi MMHM. Two distinct squamous cell carcinomas in a psoriasis patient receiving low-dose cyclosporine maintenance treatment. J Am Acad Dermatol. 1989;21:1305-6.
125. Agnew KL, Bunker CB. Multiple cutaneous squamous carcinoma in a psoriatic associated with cyclosporin, alcohol abuse and ultraviolet radiation exposure which were suppressed by acitretin. J Eur Acad Dermatol Venereol. 2003;17:113-14.
126. Green C, Hawk JLM. Cutaneous malignancy related to cyclosporin A therapy. Clin Exp Dermatol. 1993;18:30-1.
127. Korstanje MJ, van de Staak WJBM. High cumulative dose of ultraviolet radiation is a contraindication for cyclosporin therapy. Clin Exp Dermatol. 1990;15:76.
128. Marcil I, Stern RS. Squamous-cell cancer of the skin in patients given PUVA and cyclosporin: nested cohort crossover study. Lancet. 2001;358:1042-5.
129. Ross M, Goodman MM, Barr RJ, Liao SY. Multiple eruptive benign keratoses associated with cyclosporine therapy for psoriasis. J Am Acad Dermatol. 1992;26:128-9.
130. Yamamoto T, Watanabe K, Katayama I, Nishioka K. Multiple benign keratoses during cyclosporin therapy for psoriasis. J Dermatol. 1995;22:298-9.
131. De Felipe I, Redondo P. Eruptive angiomas after treatment with cyclosporine in a patient with psoriasis. Arch Dermatol. 1998;134:1487-8.
132. Stiller MJ, Pak GH, Kenny C, Jandreau L, Davis I, Wachsman S, et al. Elevation of fasting serum lipids in patients treated with low-dose cyclosporine for severe plaque-type psoriasis: an assessment of clinical significance when viewed as a risk factor for cardiovascular disease. J Am Acad Dermatol. 1992;27:434-8.
133. Elzinga L, Kelley VE, Houghton DC, Bennett WM. Modification of experimental nephrotoxicity with fish oil as the vehicle for cyclosporine. Transplant. 1987;43:271-4.
134. Stoof TJ, Korstanje MJ, Bilo HJG, Starink TM, Hulsmans RF, Donker AJ. Does fish oil protect renal function in cyclosporin-treated psoriasis patients? J Intern Med. 1989;226:437-11.
135. Lipscombe J, Lewis GF, Cattran D, Bargman JM. Deterioration in renal function associated with fibrate therapy. Clin Nephrol. 2001;55:39-44.
136. Hanes DS, Nicholson PG, Raval DD, Hooper FL, Behrens MT, Weir MR. A crossover comparison of the efficacy and safety of lovastatin and gemfibrozil in the treatment of hyperlipidemic organ transplant patients. Am J Ther. 1997;4:85-91.
137. Miller DB, Spence JD. Clinical pharmacokinetics of fibric acid derivatives (Fibrates). Clin Pharmacokinet. 1998;34:155-62.
138. Bays HE, Dujovne CA. Drug interactions of lipid-altering drugs. Drug Saf. 1998;19:355-71.
139. Christians U, Jacobsen W, Floren LC. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? Pharmacol Ther. 1998;80:1-34.
140. Capone D, Stanziale P, Gentile A, Imperatore P, Pellegrino T, Basile V. Effects of simvastatin and pravastatin on hyperlipidemia and cyclosporin blood levels in renal transplant recipients. Am J Nephrol. 1999;19:411-15.
141. Olbricht C, Wanner C, Eisenhauer T, Kliem V, Doll R, Boddaert M, et al. Accumulation of lovastatin, but not pravastatin in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin Pharmacol Ther. 1997;62:311-21.
142. Rodriguez JA, Crespo-Leiro MG, Paniagua MJ, Cuenca JJ, Hermida LF, Juffe A, et al. Rhabdomyolysis in heart transplant patients on HMG-CoA reductase inhibitors and cyclosporine. Transplant Proc. 1999;31:2522-3.
143. Keogh A, Macdonald P, Kaan A, Aboyoun C, Spratt P, Mundy J. Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation. J Heart Lung Transplant. 2000;19:529-37.
144. Everett DW, Chando TJ, Didonato GC, Singhvi SM, Pan HY, Weinstein SH. Biotransforrnation of pravastatin sodium in humans. Drug Metab Dispos. 1991;19:740-8.
145. Teuscher AU, Seaquist ER, Pittelkow MR, Robertson RP. Effect of long-term cyclosporine and long-term prednisone therapy on insulin secretory reserve. Schweiz Med Wochenschr. 1994;124:2036-8.
146. Krentz AJ, Dousset B, Mayer D, McMaster P, Buckels J, Cramb R, et al. Metabolic effects of cyclosporin A and FK 506 in liver transplant recipients. Diabetes. 1993;42:1753-9.
147. Neto AB, Haapalainen E, Ferreira R, Feo CF, Misiako EP, Vennarecci G, et al. Metabolic and ultrastructural effects of cyclosporin A on pancreatic islets. Transplant Int. 1999;12:208-12.
148. Goldman M. Uric acid in the etiology of psoriasis. Am J Dermatopathol. 1981;3:397-404.
149. Zurcher RM, Bock HA, Thiel G. Excellent uricosuric efficacy of benzbromarone in cyclosporin-A-treated renal transplant patients: a prospective study. Nephrol Dial Transplant. 1994;9:548-51.
150. Thiel G, Bock A, Spondlin M, Brunner EP, Mihatsch M, Rufli T, et al. Long-term benefits and risks of cyclosporin A (sandimmun) - an analysis at 10 years. Transplant Proc. 1994;26:2493-8.
151. De Rie, Meinardi MMHM, Bos JD. Analysis of side effects of medium- and low-dose cyclosporin maintenance therapy in psoriasis. Br J Dermatol. 1990;123:347-53.
152. Balletta M, Libetta C, Fuiano G, Delfino M, Brunetti B, Ungaro B, et al. Effects of a two-month treatment with low oral doses of cyclosporin on renal function. Nephrol Dial Transplant. 1991;6:324-9.
153. Kirby B, Rogers S. Gingival hyperplasia in psoriasis patients treated with cyclosporin. Br J Dermatol. 2000;25:96-9.
154. Thami GP, Bhalla M. Erythromelalgia induced by possible calcium channel blockade by cyclosporin. BMJ. 2003; 326:910.
155. Cacoub P, Artru L, Canesi M, Koeger AC, Camus JP. Life-threatening psoriasis relapse on withdrawal of cyclosporin. Lancet. 1988;II:219-20.
156. Heidenheim M, Oxholm A, Da Cunha Bang F. Generalised pustular psoriasis in relation to withdrawal of cyclosporin A. Br J Dermatol. 1990;122:719.
157. Mahendran R, Grech C. Generalised pustular psoriasis following a short course of cyclosporin (Neoral). Br J Dermatol. 1998;139:934.
158. Georgala S, Koumantaki E, Rallis E, Papadavid E. Generalized pustular psoriasis developing during withdrawal of short-term cyclosporin therapy. Br J Dermatol. 2000;142:1047-70.
159. Kamarashev J, Lor P, Forster A, Heinzerling L, Burg G, Nestle FO. Generalised pustular psoriasis induced by cyclosporin A withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept. Dermatology. 2002;205:213-16.
160. De Silva BD, Benton EC, Tidman MJ. Generalised pustular psoriasis following withdrawal of oral cyclosporin treatment for palmo-plantar pustulosis. Clin Exp Dermatol. 1999;24:10-13.
161. Ho VC, Griffiths CEM, Albrecht G, Vanaclocha F, Leon-Dorantes G, Atakan N, et al. Intermittent short courses of cyclosporin (Neoral®) for psoriasis unresponsive to topical therapy. Br J Dermatol. 1999;141:283-91.
162. Berth-Jones J, Voorhees JJ. Consensus conference on cyclosporin A microemulsion for psoriasis, June 1996. Br J Dermatol. 1996;135:775-7.
163. Oztas P, Gurer MA. The evaluation of the effectiveness and side-effects of a 200-mg/day constant dose of cyclosporin in chronic plaque-type psoriasis: can a constant dose be an alternative? J Eur Acad Dermatol Venereol. 2004;18:103-4.
164. Thaçi D, Bräutigam M, Kaufmann R, Weidinger G, Paul C, Christophers E. Body-weight-independent dosing of cyclosporine micro-emulsion and three times weekly maintenance regimen in severe psoriasis. A randomised study. Dermatology. 2002;205:383-8.
165. Ho VCY, Griffiths CEM, Berth-Jones J, Papp KA, Vanaclocha F, Dauden E, et al. Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study. J Am Acad Dermatol. 2001;44:643-51.
166. Ohtsuki M, Nakagawa H, Sugai J, Ozawa A, Ohkido M, Nakayama J, et al. Long-term continuous versus intermittent cyclosporin: therapy for psoriasis. J Dermatol. 2003;30:290-8.
167. Korstanje MJ. Cyclosporin A administration in dermatology: once a day or in fractional doses? Arch Derm Res. 1990;281:536-7.
168. Meinardi MM, Bos JD. Cyclosporine maintenance therapy in psoriasis. Transplant Proc. 1988;20(Suppl 4):42-9.
169. Munro CS, Levell NJ, Shuster S, Friedmann PS. Maintenance treatment with cyclosporin in atopic eczema. Br J Dermatol. 1994;130:376-80.
170. Harper SJ, Moorhouse J, Abrams K, Jurewicz A, Nicholson M, Horsburgh T, et al. The beneficial effects of oral nifedipine on cyclosporin-treated renal transplant recipients - a randomised population study. Transplant Int. 1996;9:115-25.
171. McNally PG, Walls J, Feehally J. The effect on renal function in normotensive cyclosporin-A-treated renal allograft recipients. Nephrol Dial Transplant. 1990;5:962-8.
172. Edwards BD, Chalmers RJG, O'Driscoll J, Lawson RS, Testa HJ, Ballardie FW. Modulation of abnormalities in renal haemodynamics and vasoactive mediators by nifedipine in patients with psoriasis on low-dose cyclosporin. Nephrol Dial Transplant. 1993;8:1071-8.
173. McCulloch TA, Harper SJ, Donnelly PK, Moorhouse J, Bell PR, Walls J, et al. Influence of nifedipine on interstitial fibrosis in renal transplant allografts treated with cyclosporin A. J Clin Pathol. 1994;47:839-42.
174. Raman GV, Campbell SK, Farrer A, Albano JD, Cook J. Modifying effects of amlodipine on cyclosporin A-induced changes in renal function in patients with psoriasis. J Hypertens Suppl. 1998;16:S39-S41.
175. Neumayer HH, Kunzendorf U, Schreiber M. Protective effects of calcium antagonists in human renal transplantation. Kidney Int. 1992;36(Suppl):S87-S93.
176. Chan C, Maurer J, Cardella C, Cattran D, Pei Y. A randomized controlled trial of verapamil on cyclosporine nephrotoxicity in heart and lung transplant recipients. Transplantation. 1997;63:1435-40.
177. Deray G, Baumelou B, Le Hoang P, Aupetit B, Girard B, Baumelau A, et al. Enhancement of cyclosporin nephrotoxicity by diuretic therapy. Clin Nephrol. 1989;32:47.
178. Feutren G, Miller C. Low predictive value of cyclosporine level for efficacy or renal dysfunction in psoriasis and idiopathic nephrotic syndrome. Transplant Proc. 1990;22:1299-302.
179. Young EW, Ellis CN, Messana JM, Johnson KJ, Leichtman AB, Mihatsch MJ, et al. A prospective study of renal structure and function in psoriasis patients treated with cyclosporin. Kidney Int. 1994;46:1216-22.
180. Pei Y, Scholey JW, Katz A, Schachter R, Murphy GF, Cattran D. Chronic nephrotoxicity in psoriatic patients treated with cyclosporine. Am J Kidney Dis. 1994;23:528-36.
181. Heydendael VM, Spuls PI, Ten Berge IJ, Opmeer BC, Bos JD, de Rie MA. Cyclosporin trough levels: is monitoring necessary during short-term treatment in psoriasis? A systematic review and clinical data on trough levels. Br J Dermatol. 2002;147:122-9.
182. Lindholm A, Zachariae H, Reitamo S, Ibsen HH, Oxholm A, Reunala T, et al. Is cyclosporine blood concentration monitoring necessary in patients treated
183. Korstanje MJ, Bilo HJG, Stoof TJ. Sustained renal function loss in psoriasis patients after withdrawal of low-dose cyclosporin therapy. Br J Dermatol. 1992;127:501-4.
184. Powles AV, Cook T, Hulme B, Baker BS, Lewis HM, Thomas E, et al. Renal function and biopsy findings after 5 years' treatment with low-dose cyclosporin for psoriasis. Br J Dermatol. 1993;128:159-65.
185. García-Bustínduy M, Escoda M, Guimerá FJ, Saez M, Dorta S, Fagundo E, et al. Safety of long-term treatment with cyclosporin A in resistant chronic plaque psoriasis: a retrospective case series. J Eur Acad Dermatol Venereol. 2004;18:169-72.
186. Markham T, Watson A, Rogers S. Adverse effects with long-term cyclosporin for severe psoriasis. Clin Exp Dermatol. 2002;27:111-14.
187. Kelly PA, Wang H, Napoli KL, Kahan BD, Strobel HW. Metabolism of cyclosporine by cytochromes P450 3A9 and 3A4. Eur J Drug Metab Pharmacokinet. 1999;24:321-8.
188. Durr D, Steiger B, Kullak-Ublick GA, Rensch KM, Steinert HC, Meier PJ, et al. St John's wort induces intestinal P-glycoprotein/MDR1 and hepatic CYP3A4. Clin Pharmacol Ther. 2000;68:598-60.
189. Moore LB, Goodwin B, Jones SA, Wisely GB, Serabjit-Singh CJ, Willson TM, et al. St John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci U S A. 2000;97:7500-2.
190. Karliova M, Treichel U, Malago M, Frilling A, Gerken G, Broelsch CE. Interaction of Hypericum perforatum (St John's wort) with cyclosporin A metabolism in a patient after liver transplantation. J Hepatol. 2000;33:853-5.
191. Ducharme MP, Provenzano R, Dehoorne-Smith M, Edwards DJ. Trough concentrations of cyclosporine in blood following administration with grapefruit juice. Br J Clin Pharmacol. 1993;36:457-9.
192. Herlitz H, Edgar B, Hedner T, Lidman K, Karlberg I. Grapefruit juice: a possible source of variability in blood concentration of cyclosporin A. Nephrol Dial Transplant. 1993;8:375.
193. Yee GC, Stanley DL, Pessa LJ, Dalla Costa T, Beltz SE, Ruiz J, et al. Effect of grapefruit juice on blood cyclosporin concentration. Lancet. 1995;345:955-6.
194. Bistrup C, Nielsen FT, Jeppesen UE, Dieperink H. Effect of grapefruit juice on Sandimmun Neoral™ absorption among stable renal allograft recipients. Nephrol Dialysis Transpl. 2001;16:373-7.
195. Bailey DG, Arnold JMO, Spence JD. Grapefruit juice and drugs: how significant is the interaction? Clin Pharmacokinet. 1994;26:91-8.
196. Gueco IP, Tan-Torres T, Baniga U, Alano F. Ketoconazole in posttransplant triple therapy: comparison of costs and outcomes. Transplant Proc. 1992;24:1709-14.
197. First MR, Schroeder TJ, Michael A, Hariharan S, Weiskittel P, Alexander JW. Safety and efficacy of long-term cyclosporine-ketoconazole administration and preliminary results of a randomized trial. Transplant Proc. 1993;25:591-4.
198. Moody HR, Bickell-Feist L, Friesen I, Huizinga R, Halloran PF, et al. Benefits of cyclosporine dose reduction using diltiazem. Clin Invest Med. 1991;14(Suppl):A142.
199. Patton PR, Brunson ME, Pfaff WW, Howard RJ, Peterson JC, Ramos EL, et al. A preliminary report of diltiazem and ketoconazole: their cyclosporine-sparing effect and impact on transplant outcome. Transplantation. 1994;57:889-92.
200. Anonymous. Cyclosporin-sparing agents provide potential economic benefit. Drugs & Therapy Perspectives. 2001;17:12-15.
201. Martell R, Heinrichs D, Stiller CR, Jenner M, Keown PA, Dupre J. The effects of erythromycin in patients treated with cyclosporine. Ann Intern Med. 1986;104:660-1.
202. Freeman DJ, Martell R, Carruthers SG, Keown PA. The effect of erythromycin on the pharmacokinetics of cyclosporine. Clin Pharmacol Ther. 1986;39:193.
203. Branthwaite JP, Nicholls A. Cyclosporin and diclofenac interaction in rheumatoid arthritis. Lancet. 1991;337:252.
204. Harris KP, Jenkins D, Walls J. Nonsteroidal antiinflammatory drugs and cyclosporine. A potentially serious adverse interaction. Transplantation. 1988;46:598-9.
205. Grossman RM, Thivolet J, Claudy A, Souteyrand P, Guilhou JJ, Thomas P, et al. A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low dose cyclosporine: results of a multicenter placebo-controlled study. J Am Acad Dermatol. 1994;31:68-74.
206. Kokelj F, Torsello P, Plozzer C. Calcipotriol improves the efficacy of cyclosporine in the treatment of psoriasis vulgaris. J Eur Acad Derm Venereol. 1998;10:143-6.
207. Gottlieb SL, Heftler NS, Gilleaudeau P, Johnson R, Vallat P, Wolfe J, et al. Short-contact anthralin treatment augments therapeutic efficacy of cyclosporine in psoriasis: a clinical and pathologic study. J Am Acad Dermatol. 1995;33: 637-45.
208. Griffiths CEM, Powles AV, Baker BS, Fry L, Valdimarsson H. Combination of cyclosporine A and topical corticosteroid in the treatment of psoriasis. Transplant Proc. 1988;20(Suppl 4):50-2.
209. Clark CM, Kirby B, Morris AD, Davison S, Zaki I, Emerson R, et al. Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis. Br J Dermatol. 1999;141:279-82.
210. Brechtel B, Wellenreuther U, Toppe E, Czarnetzki BM. Combination of etretinate with cyclosporine in the treatment of severe recalcitrant psoriasis. J Am Acad Dermatol. 1994;30:1023-4.
211. Heule F, Bousema T, Laeijendecker R, vna Joost T. Three long-term regimens with cyclosporin for psoriasis vulgaris. Acta Derm Venereol (Suppl). 1989;146:171-5.
212. Korstanje MJ, Bessems PJMJ, van de Staak WJBM. Combination therapy cyclosporin-etretinate effective in erythrodermic psoriasis. Dermatologica. 1989;179:94.
213. Korstanje MJ, Van de Staak WJBM. Combination therapy cyclosporin A etretinate for psoriasis. Clin Exp Dermatol. 1990;15:172-3.
214. Shah IA, Whiting PH, Omar G, Ormerod AD, Burke MD. The effects of retinoids and terbinafine on human hepatic microsomal metabolism of cyclosporin. Br J Dermatol. 1993;129:395-8.
215. Kirby B, Harrison PV. Combination low dose CyA (Neoral) and hydroxyurea for severe recalcitrant psoriasis. Br J Dermatol. 1999;140:186-7.
216. Balasubramaniam P, Stevenson O, Berth-Jones J. Fumaric acid esters in severe psoriasis, including experience of use in combination with other systemic modalities. Br J Dermatol. 2004;150:741-6.
217. Ameen M, Smith HR, Barker JNWN. Combined mycophenolate mofetil and cyclosporin therapy for severe recalcitrant psoriasis. Clin Exp Dermatol. 2001;26:480-3.
218. Reitamo S, Spuls P, Sassolas B, Lahfa M, Claudy A, Griffiths CE, et al. Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. Br J Dermatol. 2001;145:438-45.
219. Petzelbauer P, Honigsmann H, Langer K, Strohal R, Tanew A, Wolff K, et al. Cyclosporin A in combination with photochemotherapy (PUVA) in the treatment of psoriasis. Br J Dermatol. 1990;123:641-7.
220. Bell HK, Parslew RA. Use of basiliximab as a cyclosporin-sparing agent in palmoplantar pustular psoriasis with myalgia as an adverse effect. Br J Dermatol. 2002;147:606-7.
221. Mahe E, Descamps V, Grossin M, Fraitag S, Crickx B. CD30+ T-cell lymphoma in a patient with psoriasis treated with ciclosporin and infliximab. Br J Dermatol. 2003;149:170-3.
222. Weinstein GD, White GM. An approach to the treatment of moderate to severe psoriasis with rotational therapy. J Am Acad Dermatol. 1993;28:454-9.
223. Koo J. Systemic sequential therapy of psoriasis: a new treatment paradigm for improved therapeutic results. J Am Acad Dermatol. 1999;41:S25-S28.